Annual Biotechnology Conference, free and online, is set for Nov. 5  <<Click here>>

Local Reach, Global Impact

Company Spotlight


Kannalife, Inc. Adds to Its Global IP Estate Receiving Patent Grant from Canada for Its Novel Anti-Inflammatory Compounds

Kannalife Inc. (OTCQB: KLFE), a biopharmaceutical and medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the company has been issued Canadian Patent CA2936506A1 specific to its patent known as WO2015/106108A2 titled, “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy” (the “PCT Patent”). Read more here.

[Note: Kannalife is a PABC-member company that is located at the PABC.]


FlowMetric Life Sciences and Penn State Announce a Collaboration Study on University and Community COVID-19 Antibody Testing

FlowMetric Life Sciences Inc., a global leader in immunology testing services, and the Huck Institutes of the Life Sciences at Penn State University announce the creation of a long-term collaboration study assessing the impact on the Centre County community's potential exposure to COVID-19 by Penn State University students returning to campus. Together with Penn State's Center for Clinical Research, the Huck Institutes will collect thousands of blood samples from Penn State students and members of the Centre County community at the beginning and end of each academic semester for four academic semesters. The samples will be sent to FlowMetric, a GLP-compliant, CLIA-certified, high complexity clinical laboratory located in Doylestown, Pa., for analysis. Read more here.

[Note: FlowMetric is a PABC-member company and located at the PABC.]


Arbutus Announces AB-729 90 mg Single-Dose Week 12 Data in Chronic HBV Subjects Demonstrating Significant, Continuous Reductions in HBsAg

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection as well as therapies to treat coronaviruses (including COVID-19), today reports continued positive data from an ongoing Phase 1a/1b clinical trial (AB-729-001) with AB-729, its proprietary GalNAc delivered RNAi compound. These new data demonstrate that in chronic HBV subjects, a single subcutaneous injection of 90 mg of AB-729 resulted in a mean HBsAg reduction of 1.23 log10 IU/mL at week 12. William Collier, President and Chief Executive Officer of Arbutus, stated, “The 90 mg single-dose 12-week data coupled with our previously disclosed 60 mg single-dose 12-week data mean that we now have two doses which have demonstrated meaningful reductions in HBsAg with a favorable safety and tolerability profile..." Please read more here.

[Note: Arbutus is a PABC-member company and was born at the PABC.]


Antengene Announces First Patient Dosed with ATG-010 (selinexor) for Relapsed or Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma

Antengene Corporation, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapies in oncology and hematology, announced today that it has dosed the first patient in a phase Ib clinical trial in China with ATG-010 (selinexor),an oral selective inhibitor of nuclear export (SINE) compound,for the treatment of relapsed or refractory Peripheral T-cell Lymphoma (PTCL) and NK/T-cell Lymphoma (NKTL) (TOUCH trial). This trial aims to evaluate ATG-010 (selinexor) combined with ICE regimen or GEMOX regimen and sequential ATG-010 (selinexor) monotherapy maintenance to evaluate the safety, tolerability and primary efficacy in patients with R/R PTCL and NKTL who have received at least one prior multi-agent therapy. Please read more here.

[Note: Antengene is a PABC-member company with its U.S. operations at the PABC.]


Evrys Bio awarded a supplement to its NIH National Institute for Allergy and Infectious Disease titled, "A Single Antiviral to Treat Multiple Opportunistic Infections"


 The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I STTR Grant Entitled "Soft LXR Agonists for Idiopathic Pulmonary Fibrosis"